- Home
- MBIO vs QNRX Comparison
MBIO vs QNRX Comparison
Compare MBIO & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBIO
- QNRX
- Stock Information
- Founded
- MBIO 2015
- QNRX 2018
- Country
- MBIO United States
- QNRX United States
- Employees
- MBIO N/A
- QNRX N/A
- Industry
- MBIO Biotechnology: Pharmaceutical Preparations
- QNRX Medical/Dental Instruments
- Sector
- MBIO Health Care
- QNRX Health Care
- Exchange
- MBIO Nasdaq
- QNRX Nasdaq
- Market Cap
- MBIO 4.7M
- QNRX 4.3M
- IPO Year
- MBIO N/A
- QNRX N/A
- Fundamental
- Price
- MBIO $1.43
- QNRX $7.78
- Analyst Decision
- MBIO
- QNRX
- Analyst Count
- MBIO 0
- QNRX 0
- Target Price
- MBIO N/A
- QNRX N/A
- AVG Volume (30 Days)
- MBIO 147.7K
- QNRX 2.6K
- Earning Date
- MBIO 11-07-2025
- QNRX 11-06-2025
- Dividend Yield
- MBIO N/A
- QNRX N/A
- EPS Growth
- MBIO N/A
- QNRX N/A
- EPS
- MBIO N/A
- QNRX N/A
- Revenue
- MBIO N/A
- QNRX N/A
- Revenue This Year
- MBIO N/A
- QNRX N/A
- Revenue Next Year
- MBIO N/A
- QNRX N/A
- P/E Ratio
- MBIO N/A
- QNRX N/A
- Revenue Growth
- MBIO N/A
- QNRX N/A
- 52 Week Low
- MBIO $0.89
- QNRX $5.01
- 52 Week High
- MBIO $21.95
- QNRX $54.95
- Technical
- Relative Strength Index (RSI)
- MBIO 39.31
- QNRX 55.81
- Support Level
- MBIO $1.51
- QNRX $7.39
- Resistance Level
- MBIO $1.59
- QNRX $7.74
- Average True Range (ATR)
- MBIO 0.09
- QNRX 0.17
- MACD
- MBIO -0.01
- QNRX 0.10
- Stochastic Oscillator
- MBIO 2.89
- QNRX 100.00
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.